High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitisIMAM, M. H; SINAKOS, E; PETZ, J et al.Alimentary pharmacology & therapeutics. 2011, Vol 34, Num 10, pp 1185-1192, issn 0269-2813, 8 p.Article

Accuracy and interobserver agreement of small-caliber vs. conventional esophagogastro-duodenoscopy for evaluating esophageal varicesPUNGPAPONG, S; KEAVENY, A; RAIMONDO, M et al.Endoscopy (Stuttgart). 2007, Vol 39, Num 8, pp 673-678, issn 0013-726X, 6 p.Article

Levetiracetam monotherapy for liver transplant patients with seizuresCHABOLLA, D. R; HARNOIS, D. M; MESCHIA, J. F et al.Transplantation proceedings. 2003, Vol 35, Num 4, pp 1480-1481, issn 0041-1345, 2 p.Article

Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell lineHARNOIS, D. M; QUE, F. G; CELLI, A et al.Hepatology (Baltimore, Md.). 1997, Vol 26, Num 4, pp 884-890, issn 0270-9139Article

Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?HARNOIS, D. M; GORES, G. J; LUDWIG, J et al.Journal of hepatology. 1997, Vol 27, Num 3, pp 512-516, issn 0168-8278Article

The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitisPATEL, A. H; HARNOIS, D. M; KLEE, G. G et al.The American journal of gastroenterology. 2000, Vol 95, Num 1, pp 204-207, issn 0002-9270Article

The Diagnostic Conundrum and Liver Transplantation Outcome for Combined Hepatocellular-CholangiocarcinomaPANJALA, C; SENECAL, D. L; BRIDGES, M. D et al.American journal of transplantation (Print). 2010, Vol 10, Num 5, pp 1263-1267, issn 1600-6135, 5 p.Article